Fig. 7

sox2can substitute forsox3during early otic development. (A-D) Dorsal views (anterior to the top) showing expression of pax2a at 12 hpf in a control embryo (A), a sox3-morphant (B), a hs:sox2/+ heterozygote (C) and hs:sox2/+ heterozygote injected with sox3-mo (D). Embryonic staging was confirmed with myoD expression in somites. Embryos were heat shocked at 35 °C from 10 to 12 hpf. sox3-morphants in (B) and (D) were injected with 5 ng each of sox3-mo. (E) Box-and-whisker plots of relative surface area of the otic/epibranchial domain of pax2a at 12 hpf in controls, sox3-morphants, hs:sox2/+ heterozygotes and hs:sox2/+ heterozygotes injected with sox3-mo. Data are normalized relative to control groups, with means indicated by green lines. Asterisks indicate statistically significant differences compare to control (** P<0.01, Tukey's HSD test). n.s., no significant difference compared to controls.